Cargando…
A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
BACKGROUND: Delineation of clinical target volume (CTV) for radiotherapy is a time‐consuming and labor‐intensive work. This study aims to propose a novel convolutional neural network (CNN)‐based model for fast auto‐segmentation of CTV. To evaluate its performance and clinical utility, a blind random...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704175/ https://www.ncbi.nlm.nih.gov/pubmed/34811957 http://dx.doi.org/10.1002/cam4.4441 |
_version_ | 1784621643637719040 |
---|---|
author | Wu, Yijun Kang, Kai Han, Chang Wang, Shaobin Chen, Qi Chen, Yu Zhang, Fuquan Liu, Zhikai |
author_facet | Wu, Yijun Kang, Kai Han, Chang Wang, Shaobin Chen, Qi Chen, Yu Zhang, Fuquan Liu, Zhikai |
author_sort | Wu, Yijun |
collection | PubMed |
description | BACKGROUND: Delineation of clinical target volume (CTV) for radiotherapy is a time‐consuming and labor‐intensive work. This study aims to propose a novel convolutional neural network (CNN)‐based model for fast auto‐segmentation of CTV. To evaluate its performance and clinical utility, a blind randomized validation method was used. METHODS: Our proposed model was based on the generally accepted U‐Net architecture using computed tomography slices with CTV contours delineated by experienced radiation clinicians from 135 rectal patients receiving neoadjuvant radiotherapy. The Dice similarity coefficient (DSC) and 95th percentile Hausdorff distance (95HD) were used to measure segmentation performance. The validated dataset of additional 20 patients for clinical evaluation by 10 experienced oncology clinicians from 7 centers was randomly and blindly divided into two groups for clinicians' scoring and Turing test, respectively. Second evaluation was performed with different randomization after 2 weeks. RESULTS: The mean DSC and 95HD values of the proposed model were 0.90 ± 0.02 and 8.11 ± 1.93 mm for CTV of rectal cancer patients, respectively. The average time for automatic segmentation in the validation groups was 15 s per patient. By clinicians' scoring, the AI model performed better than manually delineating, though the differences were not significant (Week 0: 2.59 vs. 2.52, p = 0.086; Week 2: 2.55 vs. 2.47, p = 0.115). Additionally, the mean positive rates in the Turing test were 40.5% in Week 0 and 45.2% in Week 2, which demonstrated the great intelligence of our model. CONCLUSIONS: Our proposed model can be used clinically for assisting contouring of CTVs in rectal cancer patients receiving neoadjuvant radiotherapy, which improves the efficiency and consistency of radiation clinicians' work. |
format | Online Article Text |
id | pubmed-8704175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87041752022-01-04 A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy Wu, Yijun Kang, Kai Han, Chang Wang, Shaobin Chen, Qi Chen, Yu Zhang, Fuquan Liu, Zhikai Cancer Med Clinical Cancer Research BACKGROUND: Delineation of clinical target volume (CTV) for radiotherapy is a time‐consuming and labor‐intensive work. This study aims to propose a novel convolutional neural network (CNN)‐based model for fast auto‐segmentation of CTV. To evaluate its performance and clinical utility, a blind randomized validation method was used. METHODS: Our proposed model was based on the generally accepted U‐Net architecture using computed tomography slices with CTV contours delineated by experienced radiation clinicians from 135 rectal patients receiving neoadjuvant radiotherapy. The Dice similarity coefficient (DSC) and 95th percentile Hausdorff distance (95HD) were used to measure segmentation performance. The validated dataset of additional 20 patients for clinical evaluation by 10 experienced oncology clinicians from 7 centers was randomly and blindly divided into two groups for clinicians' scoring and Turing test, respectively. Second evaluation was performed with different randomization after 2 weeks. RESULTS: The mean DSC and 95HD values of the proposed model were 0.90 ± 0.02 and 8.11 ± 1.93 mm for CTV of rectal cancer patients, respectively. The average time for automatic segmentation in the validation groups was 15 s per patient. By clinicians' scoring, the AI model performed better than manually delineating, though the differences were not significant (Week 0: 2.59 vs. 2.52, p = 0.086; Week 2: 2.55 vs. 2.47, p = 0.115). Additionally, the mean positive rates in the Turing test were 40.5% in Week 0 and 45.2% in Week 2, which demonstrated the great intelligence of our model. CONCLUSIONS: Our proposed model can be used clinically for assisting contouring of CTVs in rectal cancer patients receiving neoadjuvant radiotherapy, which improves the efficiency and consistency of radiation clinicians' work. John Wiley and Sons Inc. 2021-11-23 /pmc/articles/PMC8704175/ /pubmed/34811957 http://dx.doi.org/10.1002/cam4.4441 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Wu, Yijun Kang, Kai Han, Chang Wang, Shaobin Chen, Qi Chen, Yu Zhang, Fuquan Liu, Zhikai A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy |
title | A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy |
title_full | A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy |
title_fullStr | A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy |
title_full_unstemmed | A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy |
title_short | A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy |
title_sort | blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704175/ https://www.ncbi.nlm.nih.gov/pubmed/34811957 http://dx.doi.org/10.1002/cam4.4441 |
work_keys_str_mv | AT wuyijun ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT kangkai ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT hanchang ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT wangshaobin ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT chenqi ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT chenyu ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT zhangfuquan ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT liuzhikai ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT wuyijun blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT kangkai blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT hanchang blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT wangshaobin blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT chenqi blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT chenyu blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT zhangfuquan blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy AT liuzhikai blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy |